Clinical Trials Logo

HER-2 Negatived Gastric Cancer clinical trials

View clinical trials related to HER-2 Negatived Gastric Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03950141 Recruiting - Clinical trials for HER-2 Negatived Gastric Cancer

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

Start date: July 1, 2017
Phase: Phase 2
Study type: Interventional

Apatinib is a novel drug which was produced by Jiangsu Hengrui Medicine Co.Ltd in China. It is approved in advanced gastric cancer(GC). The investigators just want to design such kind of trail to prove its effect when combined with S-1 as maintenance in advanced HER-2 negatived GC treated with 4 cycles chemotherapy and valued as SD. Investigators will evaluate progression free survival (PFS) and overall survival (OS).